Shoulder Innovations Inc (SI) Q4 2025 Earnings Call Transcript

Why It Matters

The results demonstrate SI‑BONE’s shift to profitable, cash‑generating growth, underpinned by strong product adoption and favorable reimbursement, positioning it as a leading player in the expanding spine‑device market.

Key Takeaways

• Q4 revenue $56.3M, up 15% YoY.
• Full-year revenue $200.9M, 20% growth.
• Adjusted EBITDA positive $5.1M in quarter.
• First quarter generated positive free cash flow.
• Smith+Nephew partnership expands trauma market access.

Pulse Analysis

Shoulder Innovations delivered a record $56.3 million fourth‑quarter revenue, a 15 % year‑over‑year increase, pushing full‑year sales to $200.9 million and surpassing the 20 % growth target. Gross margin held steady near 79 %, and operating leverage turned adjusted EBITDA positive at $5.1 million, a 176 % swing from the prior year. The company also posted its first quarter of positive free cash flow, signaling a transition from loss‑making to cash‑generating operations and reinforcing the sustainability of its growth model.

The earnings call highlighted a robust product pipeline that is fueling the top line. Intra TI secured FDA 510(k) clearance and entered an alpha launch, while a third Breakthrough Device is slated for late‑2026 commercialization. Reimbursement momentum accelerated with new NTAP and TPT designations and a 17 % Medicare uplift for office‑based labs, expanding the economic case for ambulatory surgery centers where 35 % of SI‑joint sales now occur. International demand for iFuse TORQ surged 38.8 % in Q4, prompting an accelerated launch schedule.

Strategically, SI‑BONE entered a national trauma partnership with Smith + Nephew, unlocking level‑1 and level‑2 trauma center distribution and broadening its addressable market. The guidance for 2026 projects $228.5‑$232.5 million revenue, reflecting 14‑16 % growth with continued margin expansion. Management’s focus on expanding the hybrid sales force, adding ten new territories, and promoting market‑access leadership positions the company to capture shifting spine‑care reimbursement policies and the migration of procedures to lower‑cost settings, making it a compelling play for investors seeking exposure to high‑margin medical‑device growth.